0001127602-24-008505.txt : 20240305
0001127602-24-008505.hdr.sgml : 20240305
20240305160701
ACCESSION NUMBER: 0001127602-24-008505
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Francois Cedric
CENTRAL INDEX KEY: 0001658080
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24720319
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-03-01
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001658080
Francois Cedric
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
1
Chief Executive Officer
1
Common Stock
532946
I
Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2)
Common Stock
654211
I
Indirect Owner (The Cedric Francois Irrevocable Trust of 2023)
Common Stock
300000
I
Indirect Owner (The Francois Grossi Trust)
Common Stock
234411
I
Indirect Owner (The Francois-DuBois Educational Trust)
Common Stock
2024-03-01
4
M
0
50000
3.76
A
363662
D
Common Stock
2024-03-01
4
M
0
200000
4.31
A
563662
D
Common Stock
2024-03-01
4
S
0
28868
62.213
D
534794
D
Common Stock
2024-03-01
4
S
0
41704
62.9631
D
493090
D
Common Stock
2024-03-01
4
S
0
62503
64.2573
D
430587
D
Common Stock
2024-03-01
4
S
0
116512
64.9163
D
314075
D
Common Stock
2024-03-01
4
S
0
413
65.68
D
313662
D
Stock Option (Right to Buy)
3.76
2024-03-01
4
M
0
50000
0
D
2026-02-06
Common Stock
50000
8840
D
Stock Option (Right to Buy)
4.31
2024-03-01
4
M
0
200000
0
D
2027-08-20
Common Stock
200000
175538
D
The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.
The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
This transaction was executed in multiple trades at prices ranging from $61.615 - $62.605. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.61 - $63.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $63.665 - $64.645. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $64.6575 - $65.59 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $65.67 - $65.69 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on February 8, 2016 and fully vested.
This option was granted on August 21, 2017 and is fully vested.
/s/ David Watson, attorney-in-fact for Cedric Francois
2024-03-05